Kiromic Biopharma Pipeline To Prioritize A New Gamma Delta T-Cell Product Candidate
Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
IND for Non-Engineered Deltacel/KB-GDT™ to be Submitted in the Second Half of 2022 with Beginning of Clinical Trial